TGTX Yann Echelard sells $490K worth of shares
Nov 09, 2024, 8:31 AM
14.86%
What does TGTX do
TG Therapeutics, based in Morrisville, North Carolina, develops treatments for B-cell malignancies and autoimmune diseases, with key candidates including Ublituximab, TG-1701, and TG-1801. The company employs 284 people and explores partnership opportunities for additional products.
Yann Echelard sold 20,000 shares of TGTX on 5 November at $24.48 per share, worth a total of $490K. They now own 224,098 TGTX shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.